DALLAS, June 29, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/AEZS
AEZS is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
AEterna Zentaris Inc. (AEZS) is a late-stage drug development company specializing in oncology and endocrine therapy. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its phase III program with perifosine in multiple myeloma and its phase II program in multiple cancers, including metastatic colon cancer, as well as phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Company's program is the reactivation of a phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD).
Message Board Search for AEZS: http://www.boardcentral.com/boards/AEZS
In the report, the analyst notes:
"The Company recently announced a collaborative study with Almac's Diagnostics division for AEZS-108, the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, which is being investigated in multiple cancers. The Company said the collaboration is aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.
"AEZS last week announced that it has completed its previously announced registered direct offering of $12.1 million units comprised of common shares and common share purchase warrants to certain institutional investors ... According to the Company, proceeds from the transaction will be used to fund its AEZS-108, AEZS-112 and AEZS-130 programs and for other general corporate and working capital purposes."
To read the entire report visit: http://www.microstockprofit.com/lp/AEZS
See what investors are saying about AEZS at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.